EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF - PubMed
7 hours ago
- #financial disclosures
- #pharmaceutical industry
- #clinical research
- Drs Chimura, Henderson, Jhund, Claggett, Desai, Brinker, Lay-Flurrie, Glasauer, Goea, Berger, Lam, Senni, Voors, Zannad, Pitt, Vaduganathan, Solomon, and McMurray reported various financial disclosures including grants, personal fees, employment, consultancy, and patents related to pharmaceutical companies and medical organizations.
- Disclosures involve companies such as AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Merck, Roche, and Pfizer, with activities ranging from clinical trials and advisory board fees to speaker engagements and stock holdings.
- Some individuals hold positions as directors or founders in companies like GCTP Ltd, Us2.ai, and Cardiovascular Clinical Trialists, and have pending or issued patents in medical fields.